Juno Therapeutics Enters Battle Over CAR Cancer Immunotherapy Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
University of Pennsylvania seeks court order that its cancer immunotherapy does not infringe St. Jude’s patent; Juno, which licensed the patent for the potential leukemia treatment, has joined the settlement talks.
You may also be interested in...
Juno-Novartis CAR-T Settlement Puts Focus Back In Clinic
Novartis agrees to pay Juno an initial $12.25 million, plus future milestone payments and royalties to resolve patent and contract dispute; Juno to share payments with St. Jude.
Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer
A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?
Financings Of The Fortnight Not Seeing A Trickle-Down Investment Effect From Last Year’s IPOs
The 2013 life sciences IPO boom does not necessarily augur more of the same for those biotechs now lining up to go public. Plus financing news from Juno Therapeutics, GlycoMimetics, Ultragenyx and Alkermes.